EU extends label of Cinryze (C1 inhibitor [human]) for children with hereditary angiodema (HAE).-Shire plc
Shire plc announced that the European Commission (EC) has approved a label extension granting three new indications for Cinryze (C1 inhibitor [human]), broadening its use to children with Hereditary angiodema (HAE), a rare, genetic disorder that results in recurring attacks of edema (swelling). The body sites most commonly affected are mainly the extremities and abdomen.
Cinryze is now indicated for routine prevention of angioedema attacks in children (ages 6 years and above) with severe and recurrent attacks of HAE who are intolerant to or insufficiently protected by oral preventions treatments, or patients who are inadequately managed with repeated acute treatment. It is the first and only HAE treatment with this indication in paediatric patients.
Cinryze is also now approved for the treatment and pre-procedure prevention of angioedema attacks in children (ages 2 years and above) with HAE. Symptoms of HAE often present in childhood, and while attacks can occur at any age, early onset may predict a more severe disease course. Attacks often occur in children without a clear trigger, and may affect a child�s participation in school, activities, and sports, which can leave them feeling socially isolated. Less frequently, HAE can cause life-threatening attacks due to obstruction in the upper airways.
Related news and insights
Amicus Therapeutics announced that the European Medicines Agency validated the Marketing Authorization Applications (MAA) for AT GAA (cipaglucosidase alfa + miglustat), the Company’s investigational two-component therapy for the treatment of Pompe disease.
Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia.
BeiGene, Ltd. and EUSA Pharma (UK), Ltd. announced that the China National Medical Products Administration (NMPA) has approved Sylvant (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD).